Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109,877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Yue D, et al. Among authors: yang f, yang y. Lancet Respir Med. 2024 Nov 21:S2213-2600(24)00269-8. doi: 10.1016/S2213-2600(24)00269-8. Online ahead of print. Lancet Respir Med. 2024. PMID: 39581197
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Yue D, et al. Among authors: yang y. Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24. Lancet Respir Med. 2018. PMID: 30150014 Clinical Trial.
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Ni J, Huang M, Zhang L, Wu N, Bai CX, Chen LA, Liang J, Liu Q, Wang J, Wu YL, Zhang FC, Zhang SY, Chen C, Chen J, Fang WT, Gao SG, Hu J, Jiang T, Li SQ, Li HC, Liao YD, Liu Y, Liu DR, Liu HX, Liu JY, Liu LX, Wang MZ, Wang CL, Yang F, Yang Y, Zhang LJ, Zhi XY, Zhong WZ, Guan YZ, Guo XX, He CX, Li SL, Li Y, Liang NX, Lu FL, Lv C, Lv W, Si XY, Tan FW, Wang HP, Wang JS, Yan S, Yang HX, Zhu HJ, Zhuang JL, Zhuo ML. Ni J, et al. Among authors: yang f, yang hx, yang y. Thorac Cancer. 2021 May;12(9):1469-1488. doi: 10.1111/1759-7714.13942. Epub 2021 Mar 30. Thorac Cancer. 2021. PMID: 33787090 Free PMC article.
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer].
Ni J, Huang M, Zhang L, Wu N, Bai C, Chen L, Liang J, Liu Q, Wang J, Wu Y, Zhang F, Zhang S, Chen C, Chen J, Fang W, Gao S, Hu J, Jiang T, Li S, Li H, Liao Y, Liu Y, Liu D, Liu H, Liu J, Liu L, Wang M, Wang C, Yang F, Yang Y, Zhang L, Zhi X, Zhong W, Guan Y, Guo X, He C, Li S, Li Y, Liang N, Lu F, Lv C, Lv W, Si X, Tan F, Wang H, Wang J, Yan S, Yang H, Zhu H, Zhuang J, Zhuo M. Ni J, et al. Among authors: yang f, yang h, yang y. Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):141-160. doi: 10.3779/j.issn.1009-3419.2021.101.06. Zhongguo Fei Ai Za Zhi. 2021. PMID: 33819964 Free PMC article. Chinese.
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Zhang Z, Zhang B, Wang C. Yue D, et al. Among authors: yang y. J Clin Oncol. 2022 Dec 1;40(34):3912-3917. doi: 10.1200/JCO.22.00428. Epub 2022 Aug 26. J Clin Oncol. 2022. PMID: 36027483 Clinical Trial.
International expert consensus on immunotherapy for early-stage non-small cell lung cancer.
Liang W, Cai K, Cao Q, Chen C, Chen H, Chen J, Chen KN, Chen Q, Chu T, Dong Y, Fan J, Fang W, Fu J, Fu X, Gao S, Ge D, Geng G, Geng Q, He J, Hu J, Hu J, Hu WD, Jiang F, Jiang T, Jiao W, Li HC, Li Q, Li S, Li S, Li X, Liao YD, Liu C, Liu H, Liu Y, Lu Z, Luo Q, Ma H, Pan X, Qiao G, Ren S, Shen W, Song Y, Sun D, Wang G, Wang J, Wang M, Wang Q, Wang WX, Wei L, Wu M, Wu N, Xia H, Xu SD, Yang F, Yang K, Yang Y, Yu F, Yu ZT, Yue DS, Zhang L, Zhang W, Zhang Z, Zhao G, Zhao J, Zhao X, Zhou C, Zhou Q, Zhu K, Zhu Y, Hida T, Dempke WCM, Rossi A, de Perrot M, Ramirez RA, Provencio M, Lee JM, Passaro A, Spaggiari L, Spicer J, Girard N, Forde PM, Mok TSK, Cascone T, He J. Liang W, et al. Among authors: yang f, yang k, yang y. Transl Lung Cancer Res. 2022 Sep;11(9):1742-1762. doi: 10.21037/tlcr-22-617. Transl Lung Cancer Res. 2022. PMID: 36248334 Free PMC article. Review. No abstract available.
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J; written on behalf of National Clinical Research Center for Respiratory Disease; Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare; Chinese Alliance Against Lung Cancer; AME Thoracic Surgery Collaborative Group. Liang W, et al. Among authors: yang y. Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Transl Lung Cancer Res. 2019. PMID: 32010594 Free PMC article. Review. No abstract available.
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. Yue D, et al. Among authors: yang c, yang y. PLoS One. 2015 Jul 1;10(7):e0132134. doi: 10.1371/journal.pone.0132134. eCollection 2015. PLoS One. 2015. PMID: 26132438 Free PMC article.
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, Wang J, Wang R, Ji C, Li S, Wang Y, Yan S, Lu F, Pei Y, Liu Y, Yang Y. Lv C, et al. Among authors: yang y. Lung Cancer. 2023 Apr;178:151-156. doi: 10.1016/j.lungcan.2023.02.011. Epub 2023 Feb 17. Lung Cancer. 2023. PMID: 36863124 Free article. Clinical Trial.
Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011).
Zhi XY, Wu YL, Bu H, Cheng G, Cheng Y, Du X, Han BH, Jiang GN, Jiao SC, Liu DR, Liu LX, Lu Y, Ma SL, Shi YK, Wang CL, Wang J, Wang TY, Yang Y, Zhou QH; Lung Cancer Diagnosis and Treatment Expert Panel of the Chinese Ministry of Health. Zhi XY, et al. Among authors: yang y. J Thorac Dis. 2012 Feb;4(1):88-101. doi: 10.3978/j.issn.2072-1439.2010.08.01. J Thorac Dis. 2012. PMID: 22295172 Free PMC article. No abstract available.
109,877 results
You have reached the last available page of results. Please see the User Guide for more information.